Company: VERA
Filing Date: 2025-06-02
Form Type: 8-K
Source: 0001193125-25-132736
Chunk: 0

Company: Vera Therapeutics, Inc.
Filing Date: 2025-06-02
Form: 8-K
Item: Item 7.01
Chunk 0
---
Item 7.01      Regulation FD Disclosure.  

On June 2, 2025, Vera Therapeutics, Inc. (the “ Company”) announced positive36-weekdata from the Company’s ORIGIN Phase 3 clinical trial of atacicept in adult patients with immunoglobulin A nephropathy (“ IgAN”). A copy of the press release is furnished as Exhibit 99.1. In connection with the data release, the Company compiled a presentation entitled “ Origin Phase 3 Topline Results” (the “ Presentation”) that includes the week 36 data from the ORIGIN Phase 3 clinical trial referenced above. A copy of the Presentation is furnished as Exhibit 99.2. For important information about forward-looking statements, see the slide titled “ Forward-Looking Statements” in Exhibit 99.2 attached hereto.

The information in this Item 7.01 of this Current Report on Form8-K, including Exhibits 99.1 and 99.2, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 7.01, including Exhibits 99.1 and 99.2, shall not be incorporated by reference into any filing with the U. S. Securities and Exchange Commission (the “ SEC”) made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.